Improving treatment in patients with lung cancer: Results from two multicentre randomised studies
Doctoral thesis
Permanent lenke
http://hdl.handle.net/11250/263329Utgivelsesdato
2006Metadata
Vis full innførselSamlinger
Består av
Sundstrøm, Stein; Bremnes, Roy M; Kaasa, Stein; Aasebø, Ulf; Hatlevoll, Reidulv; Dahle, Ragnar; Boye, Nils; Wang, Mari; Vigander, Tor; Vilsvik, Jan; Skovlund, Eva; Hannisdal, Einar; Aamdal, Steinar. Cisplatin and Etoposide Regimen Is Superior to Cyclophosphamide, Epirubicin, and Vincristine Regimen in Small-Cell Lung Cancer: Results From a Randomized Phase III Trial With 5 Years’ Follow-Up. Journal of Clinical Oncology. 20(24): 4665-4672, 2002.Sundstrøm, Stein; Bremnes, Roy M; Kaasa, Stein; Aasebø, Ulf; Aamdal, Steinar. Second-line chemotherapy in recurrent small cell lung cancerResults from a crossover schedule after primary treatment with cisplatin and etoposide (EP-regimen) or cyclophosphamide, epirubicin, and vincristin (CEV-regimen). Lung Cancer. 48(2): 251-261, 2005.
Sundstrøm, Stein; Bremnes, Roy M; Aasebø, Ulf; Aamdal, Steinar; Hatlevoll, Reidulv; Brunsvig, Paal; Johannessen, Dag Clement; Klepp, Olbjørn; Fayvers, Peter M; Kaasa, Stein. Hypofractionated Palliative Radiotherapy (17 Gy per two fractions) in Advanced Non–Small-Cell Lung Carcinoma Is Comparable to Standard Fractionation for Symptom Control and Survival. Journal of Clinical Oncology. 22(5): 765-768, 2004.
Sundstrøm, Stein; Bremnes, Roy M; Brunsvig, Paal; Aasebø, Ulf; Klepp, Olbjørn; Fayvers, Peter M; Kaasa, Stein. Immediate or delayed radiotherapy in advanced non-small cell lung cancer (NSCLC)?. Radiotherapy and Oncology. 75(2): 141-148, 2005.